Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: A systematic review and network meta-analysis.
about
The safety of edoxaban for treating atrial fibrillation.Predicting in a predicament: Stroke and hemorrhage risk prediction in dialysis patients with atrial fibrillation.Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerationsWATCHMAN device-related thrombus successfully treated with apixaban: A case report.Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation.A multi-hospital analysis of predictors of oral anticoagulation prescriptions for patients with actionable atrial fibrillation who attend the emergency department.Anti-thrombotic therapy for atrial fibrillation in patients with chronic kidney disease: Current views.
P2860
Q38598266-DA47D9E3-4D75-4296-9B2A-ADD4689BCDCFQ38683015-CE7FF769-7F4D-4B9D-9A1A-FD1AD6EC75EDQ38707885-2186570E-FFDB-40BD-B2AD-D92177995145Q47104894-23FC10D4-DF02-4A1D-AD78-3D36F0FE47CEQ47365787-D91E21A9-FA79-4373-95A8-AE5BE1CCF268Q47398263-1D400EDC-B6F8-404B-9A52-73E14FAFB9D6Q50075292-AE5FA7B1-934A-431B-926B-D730E5833594
P2860
Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: A systematic review and network meta-analysis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Non-vitamin K antagonist oral ...... iew and network meta-analysis.
@en
Non-vitamin K antagonist oral ...... iew and network meta-analysis.
@nl
type
label
Non-vitamin K antagonist oral ...... iew and network meta-analysis.
@en
Non-vitamin K antagonist oral ...... iew and network meta-analysis.
@nl
prefLabel
Non-vitamin K antagonist oral ...... iew and network meta-analysis.
@en
Non-vitamin K antagonist oral ...... iew and network meta-analysis.
@nl
P921
P1476
Non-vitamin K antagonist oral ...... view and network meta-analysis
@en
P2093
Giuseppe Andò
Piera Capranzano
P304
P356
10.1016/J.IJCARD.2016.11.303
P407
P577
2016-12-02T00:00:00Z